Biotech | September 16, 2025
Galimedix completes phase 1 study with oral small molecule GAL-101
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system
The cGMP-4 facility will further strengthen the company's ability to serve global partners
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The U.S. FDA issued a Form 483 with five observations
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Delegates also visited Emami’s WHO-GMP-certified manufacturing plant and Zandu Foundation for Healthcare farms for hands-on exposure to quality practices,
Subscribe To Our Newsletter & Stay Updated
